» Articles » PMID: 11137554

Human CD38: a (r)evolutionary Story of Enzymes and Receptors

Overview
Journal Leuk Res
Date 2001 Jan 4
PMID 11137554
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

Human CD38 is the mammalian prototype of a family of proteins which share structural similarities and an ectoenzymatic activity involved in the production of calcium mobilizing compounds. Besides the enzymatic activity, the molecule performs as a receptor, ruling adhesion and signaling in leukocytes. These functions are exerted through the interaction with surface ligands, one of which was identified as CD31. Recently, CD38 has gained attention as a prognostic marker and a pathogenetic agent in leukemias and in other diseases. Together these insights have produced a model of an as yet unique family of molecules, which act independently as receptors and enzymes.

Citing Articles

CAR-T cells in the treatment of multiple myeloma: an encouraging cell therapy.

Yu T, Jiao J, Wu M Front Immunol. 2025; 16:1499590.

PMID: 40078993 PMC: 11897482. DOI: 10.3389/fimmu.2025.1499590.


Preclinical evaluation of the CD38-targeting engineered toxin body MT-0169 against multiple myeloma.

Bruins W, Rentenaar R, Newcomb J, Zheng W, Ruiter R, Baardemans T Hemasphere. 2024; 8(11):e70039.

PMID: 39544624 PMC: 11561653. DOI: 10.1002/hem3.70039.


Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.

De Novellis D, Derudas D, Vincelli D, Fontana R, Pepa R, Palmieri S Eur J Haematol. 2024; 114(1):105-114.

PMID: 39370303 PMC: 11613624. DOI: 10.1111/ejh.14314.


The clinical efficacy of a daratumumab-based regimen in relapsed/refractory acute leukemia: a single-center experience.

Dai Y, Luo L, Wei Z, Cheng P, Luo J, Li J Ann Hematol. 2024; 103(10):4057-4063.

PMID: 39046511 PMC: 11512853. DOI: 10.1007/s00277-024-05892-9.


Pathways to therapy resistance: The sheltering effect of the bone marrow microenvironment to multiple myeloma cells.

Bhowmick K, von Suskil M, Al-Odat O, Elbezanti W, Jonnalagadda S, Budak-Alpdogan T Heliyon. 2024; 10(12):e33091.

PMID: 39021902 PMC: 11252793. DOI: 10.1016/j.heliyon.2024.e33091.